← Back to Clinical Trials
Recruiting NCT07425080

NCT07425080 HELIOS Advanced: Human Oocyte Illumination to Enhance Development

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07425080
Status Recruiting
Phase
Sponsor Columbia University
Condition IVF Outcomes
Study Type INTERVENTIONAL
Enrollment 270 participants
Start Date 2026-03-24
Primary Completion 2027-06-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 48 Years
Study Type INTERVENTIONAL
Interventions
Photobiomodulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 270 participants in total. It began in 2026-03-24 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Oocytes need a lot of energy to complete meiosis and fertilize successfully. As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.

Eligibility Criteria

Inclusion Criteria: * Female age between 18-48 years at the time of the IVF/ICSI cycle * Undergoing blastocyst culture * Using own oocytes * Has at least two oocytes available for randomization * Consenting to oocyte level randomization * Plan to transfer euploid embryo within 6 months Exclusion Criteria: * Use of donor oocytes or gestational carrier * Concurrent experimental laboratory inventions outside of protocol * Refusal of randomization or request for non-standard handling

Contact & Investigator

Central Contact

Samuel Zev Williams, MD, PhD

✉ zw2421@cumc.columbia.edu

📞 646-756-8282

Principal Investigator

Samuel Zev Williams, MD/PhD

PRINCIPAL INVESTIGATOR

Columbia University

Frequently Asked Questions

Who can join the NCT07425080 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 48 Years, studying IVF Outcomes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07425080 currently recruiting?

Yes, NCT07425080 is actively recruiting participants. Contact the research team at zw2421@cumc.columbia.edu for enrollment information.

Where is the NCT07425080 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07425080 clinical trial?

NCT07425080 is sponsored by Columbia University. The principal investigator is Samuel Zev Williams, MD/PhD at Columbia University. The trial plans to enroll 270 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology